Home | Publications | Healthcare place holder
place holder place holder

Healthcare

Commercial Insight: Antithrombotics

Market expands as disease management focuses on prevention

Publication Date   October 2007
Publisher   Datamonitor
Product Type   Report
Pages   236
ISBN Number   not applicable
Product Code   DAT1008
Ask a question about this product?

Price £7,600.00

approximately: $14,200 | €9,639

Summary


Datamonitor expects the antithrombotics market to peak at just over $20 billion in 2012, across the seven major markets. The growth will be driven by the uptake of the novel oral anticoagulants - Bayer's Xarelto and BI's Rendix - which are expected to launch simultaneously, in 2008.

Content


  • Chapter 1 Executive Summary
    • Objective Of The Analysis
    • Datamonitor Insight Into The Antithrombotics Market
    • Key Opinion Leaders Interviewed For This Report
  • Chapter 2 Market Definition And Overview
    • Disease Definition
    • Definition Of The Antithrombotics Market
    • Current Market Situation
    • Anticoagulants Market
    • Heparins
    • Unfractionated Heparin
    • Low Molecular Weight Heparin (Lmwh)
    • Parenteral Non-Heparinoid Anticoagulants
    • Direct Thrombin Inhibitors (Dtis)
    • Oral Anticoagulants
    • Antiplatelets Market
    • Adp Receptor Antagonists
    • Gp 2b/3a Inhibitors
  • Chapter 3 Country Market Assessments
    • National Markets
    • Anticoagulants
    • Antiplatelets
    • Current And Future Opportunities And Threats In The Antithrombotics Market
    • Global Opportunities And Threats
    • Opportunity: Increasing Patient Pool Due To Changes In Demography And Lifestyle
    • Opportunity :Big Pharma Cannot Ignore The Emerging Markets Of India And China
    • Opportunity: Increasing Co-Operation Between Regulatory Bodies
    • Threat: Cost-Conscious Pricing And Reimbursement Environment
    • Threat: Mandatory Registration Of All Clinical Trial Results
    • Threat: Increasingly Conservative Regulatory Environments
    • Threat: Ongoing Cost-Containment Measures
    • Threat: Parallel Trade
    • Increasing Generic Competition
    • Us
    • Us Opportunities
    • Price Of Drugs
    • Direct-To-Consumer Advertising
    • Us Threats
    • The Changing Healthcare Environment In The Us Will Drive Future Generic Use
    • Healthcare Expenditure Is A Concern For Many Americans
    • There Is A Variety Of Generic Substitution Policies In Place
    • Healthcare Providers Are Implementing A Range Of Incentives To Boost Generic Use
    • Medicare Part D Is Expected To Lead To Greater Generic Use
    • The Growing Role Of The Patients In Their Healthcare Choices Will Drive Generic Use
    • Pharmaceutical Reimportation
    • Formularies Promote Quality, But Restrict Choice
    • Pricing And Reimbursement Issues
    • Curbing Of Dtc Advertising Will Lead To Greater Emphasis On Risk Of Products
    • Japan
    • Japan Opportunities
    • Ageing Population
    • An Underdeveloped Generics Market Slows Brand Erosion
    • Possible Introduction Of Direct-To-Consumer Advertising
    • Multiple Patent Extensions And Labeling Regulations
    • Opening Up The Japanese Market
    • Drug Approval Lag-Time Being Targeted By The Japanese Ministry Of Health, Labor And Welfare
    • Harmonization Of Approval Process
    • The Internet Is An Effective Means To Reach Out To Patients
    • Japan Threats
    • Despite Being Underdeveloped, Generics Are Expected To Evolve Into A Significant Player In The Japanese Healthcare Market In The Future
    • Flat Sum Reimbursement
    • Complex Regulatory Process
    • Biannual Price Cuts Still Threaten Market Growth
    • New Healthcare Reforms Under Debate
    • Eu5: Opportunities And Threats
    • Eu5 Opportunities
    • Eu5 Threats
    • France: Opportunities And Threats
    • France Opportunities
    • France Threats
    • Germany: Opportunities And Threats
    • Germany Opportunities
    • Germany Threats
    • Italy: Opportunities And Threats
    • Italy Opportunities
    • Italy Threats
    • Spain: Opportunities And Threats
    • Spain Opportunities
    • Spain Threats
    • Uk: Opportunities And Threats
    • Uk Opportunities
    • Uk Threats
    • Summary Of Environmental Issues Affecting The Antithrombotic Market Size
  • Chapter 4 Forecast Analysis
    • Key Clinical Trials
    • Key Clinical Trials In The Anticoagulant Category
    • Lovenox (Enoxaparin)
    • Angiomax (Bivalirudin)
    • Arixtra (Fondaparinux)
    • Key Clinical Trials In The Antiplatelet Category
    • Plavix (Clopidogrel)
    • Key Assumptions And Events
    • New Products
    • Novel Anticoagulants
    • Xarelto (Bayer's Rivaroxaban)
    • Rendix (Boehringer Ingelheim's Dabigatran Etexilate)
    • Apixaban (Bms And Pfizer)
    • Novel Antiplatelet Agents
    • Prasugrel
    • Cangrelor (The Medicines Company)
    • Ticagrelor (Astra Zeneca)
    • Datamonitor Comment On Emerging Antiplatelet Agents
    • Future Outlook On Key Marketed Products
    • Lovenox (Enoxaparin)
    • Angiomax (Bivalirudin)
    • Arixtra (Fondaparinux)
    • Gp 2b/3a Inhibitors
    • Generic Incursion: Patent Expiries And Marketing Exclusivity
    • Limitations Of Data
    • Forecasts
  • Chapter 5 Case Studies
    • Case Study A - Clinical Unmet Need Demands A Replacement For Warfarin
    • The Limitations Of Warfarin
    • The Market Opportunity
    • Unmet Need 1: An Oral Anticoagulant That Is More Efficacious Than Warfarin In The Real-Life Clinical Setting
    • Unmet Need 2: An Oral Anticoagulant With No Monitoring Requirement
    • Unmet Need 3: An Oral Anticoagulant With Less Complex Dosing Than Warfarin
    • The Key Contenders In Development
    • The Commercial Potential Of Oral Anticoagulants
    • Patient Potential Of Oral Anticoagulants
    • Sales Forecast Of The Two Most Advanced Oral Anticoagulants
    • Forecast To 2016
    • Datamonitor Comments
    • Rivaroxaban (Bay-597939)
    • Forecasts To 2016
    • Datamonitor Comments
    • Conclusions
    • Case Study B - Review Of Legal Arguments Surrounding The Bms/Sanofi-Aventis Versus Apotex Trial Over Generic Plavix
    • The Importance Of Intellectual Property
    • Patent Protection Of Plavix (Clopidogrel)
    • Bms/Sanofi-Aventis Versus Apotex
    • Apotex Had Three Main Positions At Trial
    • Argument 2 - Inequitable Conduct
    • Argument 3 - Double Patenting
    • Verdict
    • Market Impact
    • Datamonitor Assessment Of Potential Market Impact
  • Appendix A
    • Bibliography
    • Report Methodology
    • Standard Units
    • Japanese Market Data
  • Appendix B - Market Forecast Data
    • Us Forecasts
    • Japan Forecasts
    • France Forecasts
    • Germany Forecasts
    • Italy Forecasts
    • Spain Forecasts
    • Uk Forecasts
    • M5eu Forecasts
    • 7mm Forecasts
    • About The Cardiovascular Disease Analysis Team
    • Disclaimer
  • List Of Tables
    • Table 1: Sales Of Antithrombotics In The Seven Major Markets By Drug Category, 2005-06
    • Table 2: Sales Of Anticoagulants In The Seven Major Markets By Drug Class, 2006
    • Table 3: The Heparin Market Is Dominated By Lmwhs, 2006
    • Table 4: Growth And Market Share Of The Lmwhs In The Seven Major Markets, 2006
    • Table 5: Growth And Market Share Within The Dti Subsegment Of The Parenteral Non-Heparinoid Segment, 2006
    • Table 6: Growth And Market Share Of Parenteral Non-Heparinoid Anticoagulants In The Seven Major Markets, 2006
    • Table 7: Warfarin Sales In The Seven Major Markets, 2006
    • Table 8: Sales Of Antiplatelets In The Seven Major Markets By Drug Class, 2006
    • Table 9: Sales Of Thienopyridines In The Seven Major Markets By Drug Class, 2006
    • Table 10: Gp 2b/3a Receptor Properties: Overview
    • Table 11: Growth And Market Share Within The Gp2b/3a Inhibitors, 2006
    • Table 12: Antithrombotics Market In The Seven Major Markets By Country, 2006
    • Table 13: Anticoagulant Market In The Seven Major Markets By Country, 2006
    • Table 14: Antiplatelet Market In The Seven Major Markets By Country, 2006
    • Table 15: The Ageing Population In The Seven Major Markets, 2006-2015
    • Table 16: Prevalence Of Obesity In Six Major Markets By Age (000s), 2005
    • Table 17: Prevalence Of Overweight In The Six Of The Seven Major Markets By Age (000s), 2005
    • Table 18: Patient Dynamics In Cardiovascular Conditions In The Seven Major Markets, 2005-2015 (000s)
    • Table 19: Five Generics Companies Are Among The Top 10 Companies In Terms Of Prescriptions Filled Under Medicare Part D, 2006
    • Table 20: An Example Of The Savings To Be Realized By Using Generic Drugs In The Japanese Market, 2006
    • Table 21: Key Results Of Cure Substudy
    • Table 22: Commit/Ccs-2 Trial: Efficacy Endpoints
    • Table 23: Commit/Ccs-2 Trial: Safety Endpoints
    • Table 24: Commit/Ccs-2 Trial: Time To Treatment
    • Table 25: Commit/Ccs-2 Trial: Thrombolytic Background Therapy
    • Table 26: Armyda-2: Number Of Events At 30 Days
    • Table 27: Armyda-2: Postprocedural Peak Biomarker Levels
    • Table 28: Armyda-2: Percentage Of Patients With An Elevation Of Ckmb/Troponin I
    • Table 29: Armyda-2: Number Of Bleeding Events At 30 Days
    • Table 30: Generic Incursion In The Sales Of Key Products Within The Forecasting Period, 2006-2016
    • Table 31: Phase Iii Anticoagulants (Long-Term Indications), 2006
    • Table 32: Us Antithrombotic Forecasts ($M), 2006-2016
    • Table 33: Japan Antithrombotic Forecasts ($000s), 2006-2016
    • Table 34: France Antithrombotic Forecasts ($000s), 2006-2016
    • Table 35: Germany Antithrombotic Forecasts ($000s), 2006-2016
    • Table 36: Italy Antithrombotic Forecasts ($000s), 2006-2016
    • Table 37: Spain Antithrombotic Forecasts ($000s), 2006-2016
    • Table 38: Uk Antithrombotic Forecasts ($000s), 2006-2016
    • Table 39: M5eu Antithrombotic Forecasts ($ M), 2006-2016
    • Table 40: 7mm Antithrombotic Forecasts ($ M), 2006-2016
  • List Of Figures
    • Figure 1: Sales Of Antithrombotics In The Seven Major Markets, 2006
    • Figure 2: Sales Of Anticoagulants In The Seven Major Markets By Drug Class, 2006
    • Figure 3: The Heparin Market Is Dominated By Lmwhs, 2006
    • Figure 4: The Broad Indication Roll-Out Of Lovenox (Enoxaparin) Is A Barrier To Market Entry And Penetration Of Novel Anticoagulants
    • Figure 5: Growth And Market Share Of Parenteral Non-Heparinoid Anticoagulants In The Seven Major Markets, 2006
    • Figure 6: Risk Of Stroke Increases With Age
    • Figure 7: Sales Of Antiplatelets In The Seven Major Markets By Drug Class, 2006
    • Figure 8: Antithrombotics Market In The Seven Major Markets By Country, 2006
    • Figure 9: Anticoagulant Market In The Seven Major Markets By Country, 2006
    • Figure 10: Antiplatelet Market In The Seven Major Markets By Country, 2006
    • Figure 11: Increase In Obese And Overweight Adults In The Us, 1976-2000
    • Figure 12: Generalized Distribution Chain For Parallel Traded Pharmaceutical Products
    • Figure 13: More Than Half Of All Prescriptions Dispensed In The Us Are Generics, 1994-2005
    • Figure 14: Generic Companies Dominate The Us Pharmaceutical Market In Terms Of Prescriptions
    • Figure 15: Generic Use In The Us Is Promoted Through A Number Of Channels
    • Figure 16: The Tiered Co-Payment System Will Lead To Greater Use Of Generics
    • Figure 17: Key Pressures Facing Drug Developers, 1990-2004
    • Figure 18: The Japanese Generic Market Is Underdeveloped Because Of A Number Of Factors
    • Figure 19: Although Generic Sales And Volume Use Have Increased Over The Last 10 Years, The Generics Market Only Accounts For A Small Proportion Of The Spanish Pharmaceutical Market
    • Figure 20: Summary Of Global And Eu Specific Opportunities And Threats Affecting The Antithrombotics Market, 2006
    • Figure 21: Summary Of Country-Specific Opportunities And Threats Affecting The Us And Japanese Antithrombotics Markets, 2006
    • Figure 22: Summary Of Country-Specific Opportunities And Threats Affecting The Eu5 Antithrombotics Markets, 2006
    • Figure 23: Commit/Ccs-2 Trial: Dual Antiplatelet Therapy In Ami
    • Figure 24: Armyda-2: Trial Design
    • Figure 25: Datamonitor's Projected Sales For Rendix (Dabigatran Etexilate, Bibr-1048) In Across The Seven Major Markets ($M), 2007-2016.
    • Figure 26: Datamonitor's Projected Sales For Rivaroxaban (Bay-59-7939) In Across The Seven Major Markets ($M), 2007-2016
    • Figure 27: Apotex's Argument On "Obviousness"
    • Figure 28: Apotex's Argument On "Inequitable Conduct"
    • .Figure 29: Market Share Garnered By Generic Clopidogrel
    • Figure 30: Forecast Generic Erosion Of The Plavix Brand
    • Figure 31: